한글목차

세계의 골수섬유증 표적 치료제 시장 전망은 원발성 골수섬유증, 이차성 골수섬유증 시장에 기회가 있고 유망시되고 있습니다. 세계 골수섬유증 표적 치료제 시장은 2025-2031년까지 연평균 복합 성장률(CAGR) 4.1%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 원발성 골수섬유증의 유병률 증가와 효과적인 치료에 대한 수요입니다.

• Lucintel의 예측에 따르면, 유형별로는 룩소리티닙이 예측 기간 중에 높은 성장을 이룰 전망입니다.
• 용도별로는 원발성 골수섬유증이 높은 성장을 이룰 것으로 예측됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장이 예상됩니다.

골수섬유증 표적 치료제 시장의 새로운 동향

세계의 골수섬유증 표적 치료제 시장의 새로운 동향은 이 드문 혈액암에 대한 헬스케어 시스템의 대처법을 재구성하고 있습니다. 개인화 치료의 개발, JAK 억제제의 발전, 새로운 병용 치료와 같은 주요 동향은 환자의 예후를 개선하고 있습니다. 질병 상황이 진화함에 따라 이러한 추세는 표적 약물 시장에서 혁신과 성장의 큰 기회를 제공합니다.

• JAK 억제제 치료의 진보 : 룩소리티닙과 같은 JAK 억제제는 골수섬유증 치료의 중심적 존재가 되었습니다. 현재 진행 중인 연구는 특히 기존 치료법에 저항성과 불내성을 보이는 환자에서 이러한 약물의 효능을 향상시키는 것을 목표로 합니다. 차세대 JAK 억제제는 보다 강력하고 부작용이 적고 환자의 어드히어런스를 향상시키고 치료 옵션을 크게 확장합니다.
• 개인화 및 정밀의료 : 골수섬유증 치료에서 개인화된 의료에 대한 관심이 높아지고 있으며, 유전자 프로파일링 및 바이오마커를 기반으로 한 검사가 보급되고 있습니다. 개인화된 치료를 통해 건강 관리 제공업체는 개인의 유전적 체질에 따라 치료를 조정할 수 있어 효능을 향상시키고 부작용을 최소화할 수 있습니다. 이 동향은 환자의 예후를 개선하는 표적 치료의 개발을 촉진합니다.
• 병용 요법 접근법 : JAK 억제제 및 면역조절제와 같은 다른 신규 약제를 병용하는 병용 요법은 임상시험에서 유망시되고 있습니다. 이러한 치료법은 골수섬유증의 복잡한 병태 생리를 다루고 보다 종합적인 치료 접근법을 제공하는 것을 목표로 합니다. 병용 요법은 생존율과 환자의 QOL을 개선할 것으로 기대됩니다.
• 규제 당국의 지원과 승인 증가 : 골수섬유증에 대한 인식이 증가함에 따라 규제 당국은 신약의 승인을 빠르게 진행하고 있습니다. 각국 정부는 제약회사가 희귀질환의 표적 치료제를 개발하기 위한 인센티브를 강화하고 있습니다. 이러한 약사 규제의 진전은 임상시험부터 출시까지의 기간이 단축되어 세계 골수섬유증 환자의 최첨단 치료에 대한 접근이 증가하고 있습니다.
• 세계 시장 확대 : 신흥 시장, 특히 아시아와 아프리카에서 표적 치료제의 가용성 증가는 중요한 동향입니다. 저비용 제네릭 의약품 및 현지 제조업체와의 전략적 제휴로 구명 치료에 대한 액세스가 향상되었습니다. 세계 시장 확대는 충분한 치료를 받을 수 없는 지역에서의 치료 가용성과 건강 관리 접근성을 크게 향상시킬 것으로 기대됩니다.

JAK 억제제의 진보, 맞춤형 의료, 병용 요법, 규제 상황, 세계 시장의 확대 등의 새로운 동향은 골수섬유증의 치료 상황을 일변시키는 태세입니다. 이러한 추세는 기술 혁신을 촉진하고 환자 관리를 개선하고 치료에 대한 접근성을 향상시켜 세계 골수섬유증 표적 치료제 시장 전망를 재구성하고 있습니다.

골수섬유증 표적 치료제 시장의 최근 동향

골수섬유증 표적 치료제 시장은 혁신적인 의약품 승인, 진행 중인 임상시험, 신규 치료법의 개발로 빠르게 발전하고 있습니다. 이러한 주요 발전은 치료 옵션을 재구성하고 환자의 결과를 개선하고 효과적인 치료법에 대한 액세스를 세계적으로 확대하고 있습니다.

• Fedratinib(Inrebic) 승인 : JAK2 억제제인 페드라티닙은 중위험-2 또는 고위험 골수섬유증 환자의 치료제로 FDA에 승인되었습니다. 이 승인은 룩소리티닙에 편협 또는 내성을 나타내는 환자에게 중요한 선택입니다. 페드라티닙을 사용할 수 있게 되면 골수섬유증의 치료 옵션이 다양해지고 환자 결과가 개선됩니다.
• 룩소리티닙(Jakafi) 확대 : 룩소리티닙은 골수섬유증의 기간 치료제로 계속되고 있습니다. 최근의 연구는 룩소리티닙의 효능이 골수섬유증에 그치지 않고 진성 다혈증 환자에게도 효과적인 것으로 나타났습니다. 룩소리티닙의 적응 확대 승인은 다양한 혈액 질환의 치료 상황을 크게 개선하고 있습니다.
• 개발 중인 신규 JAK 억제제 : 파클리티닙 및 모멜로티닙과 같은 몇몇 신규 JAK 억제제가 임상 개발 중입니다. 이러한 약물은 골수섬유증 환자, 특히 룩소리티닙에 반응하지 않는 환자에서 더 우수한 내약성 프로파일과 더 높은 효능을 제공하는 것을 목표로 합니다. 차세대 JAK 억제제는 환자의 치료 옵션을 확대할 것으로 기대됩니다.
• 줄기세포와 유전자치료의 임상시험 : 골수섬유증에 대한 줄기세포치료와 유전자치료를 검토하는 임상시험이 활발해지고 있습니다. 이러한 접근법은 장기적인 관해를 초래할 수 있습니다. 줄기 세포 이식은 이미 치료법의 일부이며 유전자 치료는 골수섬유증을 분자 수준에서 치료하는 미래의 방법으로 간주됩니다.
• 치료에 대한 세계적인 접근 증가 : 룩소리티닙을 포함한 골수섬유증 표적 치료제의 제네릭 의약품의 승인이 진행되고 있으며, 표적 치료제에 대한 접근이 세계적으로 확대되고 있습니다. 제약회사는 신흥 시장의 조직과 제휴하여 저렴한 의약품을 보다 널리 유통시키도록 하고 있습니다. 이러한 접근의 확대는 충분한 치료를 받지 않은 지역에서 환자 결과를 개선하는 데 도움이 됩니다.

페드라티닙과 같은 신약 승인, 룩소리티닙 적응 확대, 차세대 JAK 억제제 개발, 줄기 세포 및 유전자 치료의 진보는 골수섬유증 표적 치료제 시장을 견인하는 주요 발전입니다. 이러한 개발은 환자의 치료를 개선하고, 치료에 대한 접근성을 향상시키고, 치료 옵션을 세계적으로 확대하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계의 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 골수섬유증 표적 치료제 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• 룩소리티닙 : 동향과 예측(2019-2031년)
• 잭티닙 : 동향과 예측(2019-2031년)
• 페드라티닙 : 동향과 예측(2019-2031년)
• 파크리티닙 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제5장 세계의 골수섬유증 표적 치료제 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 원발성 골수섬유증 : 동향과 예측(2019-2031년)
• 2차성 골수섬유증 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 골수섬유증 표적 치료제 시장 : 지역별

제7장 북미의 골수섬유증 표적 치료제 시장

• 개요
• 북미의 골수섬유증 표적 치료제 시장 : 유형별
• 북미의 골수섬유증 표적 치료제 시장 : 용도별
• 미국의 골수섬유증 표적 치료제 시장
• 멕시코의 골수섬유증 표적 치료제 시장
• 캐나다 골수섬유증 표적 치료제 시장

제8장 유럽의 골수섬유증 표적 치료제 시장

• 개요
• 유럽의 골수섬유증 표적 치료제 시장 : 유형별
• 유럽의 골수섬유증 표적 치료제 시장 : 용도별
• 독일의 골수섬유증 표적 치료제 시장
• 프랑스의 골수섬유증 표적 치료제 시장
• 스페인의 골수섬유증 표적 치료제 시장
• 이탈리아의 골수섬유증 표적 치료제 시장
• 영국의 골수섬유증 표적 치료제 시장

제9장 아시아태평양의 골수섬유증 표적 치료제 시장

• 개요
• 아시아태평양의 골수섬유증 표적 치료제 시장 : 유형별
• 아시아태평양의 골수섬유증 표적 치료제 시장 : 용도별
• 일본의 골수섬유증 표적 치료제 시장
• 인도의 골수섬유증 표적 치료제 시장
• 중국의 골수섬유증 표적 치료제 시장
• 한국의 골수섬유증 표적 치료제 시장
• 인도네시아의 골수섬유증 표적 치료제 시장

제10장 기타 지역의 골수섬유증 표적 치료제 시장

• 개요
• 기타 지역의 골수섬유증 표적 치료제 시장 : 유형별
• 기타 지역의 골수섬유증 표적 치료제 시장 : 용도별
• 중동의 골수섬유증 표적 치료제 시장
• 남미의 골수섬유증 표적 치료제 시장
• 아프리카 골수섬유증 표적 치료제 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계의 골수섬유증 표적 치료제 시장에서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴, 합작 사업

제13장 밸류체인 전체에 걸친 주요 기업의 기업 프로파일

• Competitive Analysis
• Novartis
• Celgene
• Incyte
• Zelgen
• GSK Plc

제14장 부록

• 도표 일람
• 표 목록
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global myelofibrosis targeted drug market looks promising with opportunities in the primary myelofibrosis, and secondary myelofibrosis markets. The global myelofibrosis targeted drug market is expected to grow with a CAGR of 4.1% from 2025 to 2031. The major drivers for this market are increasing prevalence of primary myelofibrosis and demand for effective treatments. and advancements in targeted therapies improving patient outcomes and survival rates..

• Lucintel forecasts that, within the type category, ruxolitinib is expected to witness higher growth over the forecast period.
• Within the application category, primary myelofibrosis is expected to witness the higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Myelofibrosis Targeted Drug Market

Emerging trends in the global myelofibrosis targeted drug market are reshaping the way healthcare systems address this rare hematological cancer. Key trends such as the development of personalized therapies, JAK inhibitor advancements, and new combination treatments are improving patient outcomes. As the disease landscape evolves, these trends offer substantial opportunities for innovation and growth in the targeted drug market.

• Advances in JAK Inhibitor Therapies: JAK inhibitors like ruxolitinib have become central to myelofibrosis treatment. Ongoing research aims to improve the efficacy of these drugs, particularly in patients with resistance or intolerance to existing treatments. The next generation of JAK inhibitors offers enhanced potency, fewer side effects, and better patient adherence, significantly expanding treatment options.
• Personalized and Precision Medicine: The focus on personalized medicine in myelofibrosis treatment is growing, with genetic profiling and biomarker-based testing becoming more prevalent. Personalized treatments enable healthcare providers to tailor therapy based on an individual's genetic makeup, improving efficacy and minimizing adverse effects. This trend is fostering the development of targeted therapies that offer better patient outcomes.
• Combination Therapy Approaches: Combination therapies, such as JAK inhibitors combined with other novel agents like immune modulators, are showing promise in clinical trials. These therapies aim to address the complex pathophysiology of myelofibrosis, providing a more comprehensive treatment approach. Combination therapies are anticipated to improve survival rates and patient quality of life.
• Increased Regulatory Support and Approvals: With growing awareness of myelofibrosis, regulatory agencies are fast-tracking approvals for novel drugs. Governments are providing more incentives for pharmaceutical companies to develop targeted therapies for rare diseases. These regulatory advancements are reducing the time from clinical trials to market availability, increasing access to cutting-edge therapies for myelofibrosis patients worldwide.
• Global Market Expansion: The increasing availability of targeted drugs in emerging markets, especially in Asia and Africa, is a significant trend. Lower-cost generics and strategic collaborations with local manufacturers are improving access to life-saving treatments. The global market expansion is expected to significantly increase treatment availability and healthcare access in underserved regions.

The emerging trends of JAK inhibitor advancements, personalized medicine, combination therapies, regulatory support, and global market expansion are poised to revolutionize the treatment landscape for myelofibrosis. These trends are driving innovation, improving patient care, and providing greater accessibility to therapies, thus reshaping the future of the global myelofibrosis targeted drug market.

Recent Developments in the Myelofibrosis Targeted Drug Market

The myelofibrosis targeted drug market is evolving rapidly due to innovative drug approvals, ongoing clinical trials, and the development of novel therapies. These key developments are reshaping treatment options, improving patient outcomes, and expanding access to effective therapies globally.

• Approval of Fedratinib (Inrebic): Fedratinib, a JAK2 inhibitor, was approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis patients. This approval offers an important alternative for patients who are intolerant or resistant to ruxolitinib. The availability of fedratinib is helping diversify treatment options for myelofibrosis and improving patient outcomes.
• Ruxolitinib (Jakafi) Expansion: Ruxolitinib continues to be a cornerstone therapy for myelofibrosis. Recent studies show that its effectiveness extends beyond myelofibrosis, also benefiting patients with polycythemia vera. The approval of ruxolitinib for expanded indications is significantly improving the treatment landscape for various blood disorders.
• New JAK Inhibitors in Development: Several new JAK inhibitors, including pacritinib and momelotinib, are in clinical development. These drugs aim to offer better tolerability profiles and greater efficacy in patients with myelofibrosis, particularly those who do not respond to ruxolitinib. The next generation of JAK inhibitors is expected to expand treatment options for patients.
• Stem Cell and Gene Therapy Trials: Clinical trials investigating stem cell and gene therapies for myelofibrosis are gaining traction. These approaches offer the potential for more durable, long-term remission. Stem cell transplants are already part of the treatment arsenal, and gene therapy is seen as the future of treating myelofibrosis at a molecular level.
• Increased Global Access to Treatments: With the growing approval of generics for myelofibrosis drugs, including ruxolitinib, access to targeted therapies is expanding globally. Pharmaceutical companies are partnering with organizations in emerging markets to ensure wider distribution of affordable drugs. This increase in access is helping improve patient outcomes in underserved regions.

The approval of new drugs like fedratinib, the expansion of ruxolitinib's indications, the development of next-generation JAK inhibitors, and advancements in stem cell and gene therapy are key developments driving the myelofibrosis targeted drug market. These developments are improving patient care, increasing access to treatments, and expanding therapeutic options globally.

Strategic Growth Opportunities in the Myelofibrosis Targeted Drug Market

The global myelofibrosis targeted drug market presents several strategic growth opportunities, particularly in emerging markets, through the development of new therapies and improved access to existing treatments. Pharmaceutical companies have the chance to capitalize on these opportunities by targeting key patient demographics, expanding drug availability, and pursuing innovative research avenues.

• Emerging Market Penetration: Emerging markets such as China, India, and Southeast Asia offer significant growth potential for myelofibrosis treatments. Pharmaceutical companies can expand their reach by introducing affordable, generic versions of targeted therapies like ruxolitinib and by establishing partnerships with local healthcare providers to enhance distribution.
• Focus on Combination Therapies: Companies that invest in combination therapies targeting multiple pathways involved in myelofibrosis progression will likely find a competitive advantage. By offering treatment regimens that combine JAK inhibitors with novel agents like immunomodulators, companies can improve overall treatment efficacy and patient outcomes, which can attract a broader market.
• Personalized Treatment Solutions: Personalized medicine, especially the use of genetic profiling, will play a significant role in the treatment of myelofibrosis. Companies that develop therapies based on patient-specific genetic and molecular markers will be able to target the most appropriate treatments, enhancing the effectiveness of drugs and improving patient outcomes.
• Regulatory Approvals in Key Markets: Expediting the approval process for new treatments and focusing on gaining regulatory clearance in underserved regions will present growth opportunities. Pharmaceutical companies can navigate regulatory pathways more effectively by working closely with local authorities, enabling quicker market entry and faster patient access to therapies
• Investment in Clinical Trials and Research: There is a growing opportunity for pharmaceutical companies to invest in research for innovative treatments, including stem cell therapy, gene therapy, and next-generation JAK inhibitors. By leading clinical trials and focusing on breakthrough therapies, companies can position themselves as leaders in the myelofibrosis treatment landscape.

The global myelofibrosis targeted drug market offers numerous growth opportunities, including expansion in emerging markets, combination therapy development, personalized treatment solutions, regulatory approvals, and ongoing clinical research. These strategies can help companies increase their market share and provide better treatment options for patients with myelofibrosis.

Myelofibrosis Targeted Drug Market Driver and Challenges

The growth of the global myelofibrosis targeted drug market is influenced by a range of drivers, including advancements in drug development and increasing awareness. However, challenges such as high drug costs, regulatory hurdles, and access in underserved regions remain key factors shaping the market's trajectory.

The factors responsible for driving the Myelofibrosis Targeted Drug market include:

1. Advancements in Targeted Therapies: The development of JAK inhibitors and other targeted therapies has significantly improved treatment outcomes for myelofibrosis patients. These therapies address the root cause of the disease, making treatment more effective and driving market growth.

2. Increased Research Funding: Government and private sector investments in research are accelerating the development of new treatments. Financial support for clinical trials and drug development is helping bring novel therapies to market faster.

3. Rising Awareness of Myelofibrosis: Increased awareness about myelofibrosis, particularly in high-risk populations, is driving earlier diagnoses and higher demand for treatments. Awareness campaigns and educational initiatives are helping to identify more cases and reduce diagnostic delays.

4. Aging Population: As the global population ages, the incidence of myelofibrosis is increasing, particularly in older adults. This demographic trend is fueling demand for more effective treatments and driving growth in the targeted drug market.

5. Regulatory Support for Rare Diseases: Many governments are offering fast-track approval processes and incentives for rare disease treatments, making it easier for companies to bring new drugs to market. This support is accelerating the development of new therapies for myelofibrosis.

Challenges in the Myelofibrosis Targeted Drug market are:

1. High Cost of Treatment: The cost of targeted therapies remains a barrier to access, especially in low-income countries. High drug prices and the financial burden on patients limit the market's potential.

2. Regulatory Delays: The long regulatory approval process in certain markets can delay the availability of novel treatments. Companies must navigate complex regulatory environments to gain market approval for their products.

3. Limited Access in Rural Areas: Despite advancements, access to myelofibrosis treatments remains limited in rural and underserved regions. Poor healthcare infrastructure and distribution challenges prevent patients from receiving timely treatment.

While advancements in targeted therapies, increased research funding, and government support are driving growth in the myelofibrosis drug market, challenges such as high treatment costs, regulatory hurdles, and access limitations remain significant barriers. Addressing these challenges will be key to unlocking the full potential of this market.

List of Myelofibrosis Targeted Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myelofibrosis targeted drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myelofibrosis targeted drug companies profiled in this report include-

• Novartis
• Celgene
• Incyte
• Zelgen
• GSK Plc

Myelofibrosis Targeted Drug Market by Segment

The study includes a forecast for the global myelofibrosis targeted drug market by type, application, and region.

Myelofibrosis Targeted Drug Market by Type [Value from 2019 to 2031]:

• Ruxolitinib
• Jaktinib
• Fedratinib
• Pacritinib
• Others

Myelofibrosis Targeted Drug Market by Application [Value from 2019 to 2031]:

• Primary Myelofibrosis
• Secondary Myelofibrosis

Myelofibrosis Targeted Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Myelofibrosis Targeted Drug Market

The global myelofibrosis targeted drug market is experiencing significant growth due to increasing research and advancements in targeted therapies for this rare and debilitating blood cancer. Myelofibrosis, a type of bone marrow disorder, has seen notable developments in the form of novel drug treatments, improving patient outcomes and providing new hope for effective management. This is particularly evident in key markets like the United States, China, Germany, India, and Japan.

• United States: The United States remains at the forefront of the myelofibrosis targeted drug market, driven by the high incidence of the disease and strong investments in research and development. Recent approvals for novel JAK inhibitors, such as ruxolitinib and fedratinib, have transformed the treatment landscape. Additionally, ongoing clinical trials exploring combination therapies, such as JAK inhibitors combined with other novel agents, are likely to drive future innovations. Furthermore, the increasing adoption of personalized medicine is expected to offer tailored treatment options for myelofibrosis patients.
• China: China's myelofibrosis targeted drug market is expanding due to rising healthcare access and improved diagnostic infrastructure. The Chinese government's focus on expanding oncology treatments has led to the approval of several targeted therapies in recent years. With a growing aging population and increased awareness, the demand for myelofibrosis treatments, particularly JAK inhibitors, is on the rise. Additionally, multinational pharmaceutical companies are exploring collaborations with local Chinese manufacturers to increase drug availability and market penetration.
• Germany: Germany is a key player in the European myelofibrosis drug market, benefiting from a robust healthcare system and a high rate of medical advancements. The approval of ruxolitinib and other targeted therapies has improved survival rates for myelofibrosis patients. The market is driven by the country's strong emphasis on precision medicine and the integration of genetic testing into clinical practices. The German government's healthcare policies also support the reimbursement of myelofibrosis drugs, ensuring broader patient access to life-saving treatments.
• India: In India, the myelofibrosis targeted drug market is emerging due to the increasing diagnosis of hematological disorders and the availability of cost-effective treatments. However, challenges remain in terms of drug affordability and access, particularly in rural areas. Despite this, the Indian pharmaceutical industry's growing capacity to produce generic versions of targeted therapies, including ruxolitinib, is driving market growth. With rising awareness and improvements in healthcare infrastructure, the market for myelofibrosis therapies in India is expected to continue expanding.
• Japan: Japan is witnessing steady growth in the myelofibrosis targeted drug market, driven by high healthcare standards and the increasing aging population. Japan was one of the first countries to approve ruxolitinib for myelofibrosis treatment, and it remains a leader in adopting innovative therapies. The Japanese government has been supportive of expanding the oncology drug market, and there are ongoing efforts to integrate novel therapies such as JAK inhibitors and stem cell treatments into standard care for myelofibrosis.

Features of the Global Myelofibrosis Targeted Drug Market

• Market Size Estimates: Myelofibrosis targeted drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Myelofibrosis targeted drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: Myelofibrosis targeted drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the myelofibrosis targeted drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myelofibrosis targeted drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the myelofibrosis targeted drug market by type (ruxolitinib, jaktinib, fedratinib, pacritinib, and others), application (primary myelofibrosis and secondary myelofibrosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Myelofibrosis Targeted Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Ruxolitinib: Trends and Forecast (2019-2031)
• 4.4 Jaktinib: Trends and Forecast (2019-2031)
• 4.5 Fedratinib: Trends and Forecast (2019-2031)
• 4.6 Pacritinib: Trends and Forecast (2019-2031)
• 4.7 Others: Trends and Forecast (2019-2031)

5. Global Myelofibrosis Targeted Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Primary Myelofibrosis: Trends and Forecast (2019-2031)
• 5.4 Secondary Myelofibrosis: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Myelofibrosis Targeted Drug Market by Region

7. North American Myelofibrosis Targeted Drug Market

• 7.1 Overview
• 7.2 North American Myelofibrosis Targeted Drug Market by type
• 7.3 North American Myelofibrosis Targeted Drug Market by application
• 7.4 United States Myelofibrosis Targeted Drug Market
• 7.5 Mexican Myelofibrosis Targeted Drug Market
• 7.6 Canadian Myelofibrosis Targeted Drug Market

8. European Myelofibrosis Targeted Drug Market

• 8.1 Overview
• 8.2 European Myelofibrosis Targeted Drug Market by type
• 8.3 European Myelofibrosis Targeted Drug Market by application
• 8.4 German Myelofibrosis Targeted Drug Market
• 8.5 French Myelofibrosis Targeted Drug Market
• 8.6 Spanish Myelofibrosis Targeted Drug Market
• 8.7 Italian Myelofibrosis Targeted Drug Market
• 8.8 United Kingdom Myelofibrosis Targeted Drug Market

9. APAC Myelofibrosis Targeted Drug Market

• 9.1 Overview
• 9.2 APAC Myelofibrosis Targeted Drug Market by type
• 9.3 APAC Myelofibrosis Targeted Drug Market by application
• 9.4 Japanese Myelofibrosis Targeted Drug Market
• 9.5 Indian Myelofibrosis Targeted Drug Market
• 9.6 Chinese Myelofibrosis Targeted Drug Market
• 9.7 South Korean Myelofibrosis Targeted Drug Market
• 9.8 Indonesian Myelofibrosis Targeted Drug Market

10. ROW Myelofibrosis Targeted Drug Market

• 10.1 Overview
• 10.2 ROW Myelofibrosis Targeted Drug Market by type
• 10.3 ROW Myelofibrosis Targeted Drug Market by application
• 10.4 Middle Eastern Myelofibrosis Targeted Drug Market
• 10.5 South American Myelofibrosis Targeted Drug Market
• 10.6 African Myelofibrosis Targeted Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Myelofibrosis Targeted Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Novartis
  • Company Overview
  • Myelofibrosis Targeted Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Celgene
  • Company Overview
  • Myelofibrosis Targeted Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Incyte
  • Company Overview
  • Myelofibrosis Targeted Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Zelgen
  • Company Overview
  • Myelofibrosis Targeted Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 GSK Plc
  • Company Overview
  • Myelofibrosis Targeted Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us